Cargando…
MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
Accumulating evidence has indicated that microRNAs play a critical role in the pathogenesis of human cancers. microRNA-34a (miR-34a) has been shown to be a key regulator of tumor suppression by targeting several cancer-related signals, including the interleukin-6 receptor (IL-6R)/Signal Transducers...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690672/ https://www.ncbi.nlm.nih.gov/pubmed/31448054 http://dx.doi.org/10.18632/oncotarget.27117 |
_version_ | 1783443228366733312 |
---|---|
author | Yokomizo, Ryo Yanaihara, Nozomu Yamaguchi, Noriko Saito, Misato Kawabata, Ayako Takahashi, Kazuaki Takenaka, Masataka Yamada, Kyosuke Shapiro, Jason Solomon Okamoto, Aikou |
author_facet | Yokomizo, Ryo Yanaihara, Nozomu Yamaguchi, Noriko Saito, Misato Kawabata, Ayako Takahashi, Kazuaki Takenaka, Masataka Yamada, Kyosuke Shapiro, Jason Solomon Okamoto, Aikou |
author_sort | Yokomizo, Ryo |
collection | PubMed |
description | Accumulating evidence has indicated that microRNAs play a critical role in the pathogenesis of human cancers. microRNA-34a (miR-34a) has been shown to be a key regulator of tumor suppression by targeting several cancer-related signals, including the interleukin-6 receptor (IL-6R)/Signal Transducers and Activator of Transcription 3 (STAT3) signaling pathway. Previously, we determined that miR-34a expression was frequently reduced in high-grade serous carcinoma (HGSC), the major subtype of epithelial ovarian cancer (EOC). Considering that the IL-6R/STAT3 signaling pathway is upregulated and believed to be a potential therapeutic target in EOC, we investigated the biological significance of reduced miR-34a expression in HGSC with regard to IL-6R signaling. Additionally, we evaluated the viability of miR-34a as a therapeutic application for HGSC both in vitro and in vivo. Accordingly, we found that the ectopic expression of miR-34a significantly reduced tumor proliferation and invasion through downregulation of IL-6R expression, suggesting that reduced miR-34a expression might play an important role in the malignant potential of HGSC through upregulation of the IL-6R/STAT3 signaling pathway. Moreover, we demonstrated that replacement of miR-34a reduced tumorigenicity of HGSC in vivo. Therefore, this study may provide the rationale for miR-34a replacement as a promising therapeutic strategy for HGSC. |
format | Online Article Text |
id | pubmed-6690672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-66906722019-08-23 MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma Yokomizo, Ryo Yanaihara, Nozomu Yamaguchi, Noriko Saito, Misato Kawabata, Ayako Takahashi, Kazuaki Takenaka, Masataka Yamada, Kyosuke Shapiro, Jason Solomon Okamoto, Aikou Oncotarget Research Paper Accumulating evidence has indicated that microRNAs play a critical role in the pathogenesis of human cancers. microRNA-34a (miR-34a) has been shown to be a key regulator of tumor suppression by targeting several cancer-related signals, including the interleukin-6 receptor (IL-6R)/Signal Transducers and Activator of Transcription 3 (STAT3) signaling pathway. Previously, we determined that miR-34a expression was frequently reduced in high-grade serous carcinoma (HGSC), the major subtype of epithelial ovarian cancer (EOC). Considering that the IL-6R/STAT3 signaling pathway is upregulated and believed to be a potential therapeutic target in EOC, we investigated the biological significance of reduced miR-34a expression in HGSC with regard to IL-6R signaling. Additionally, we evaluated the viability of miR-34a as a therapeutic application for HGSC both in vitro and in vivo. Accordingly, we found that the ectopic expression of miR-34a significantly reduced tumor proliferation and invasion through downregulation of IL-6R expression, suggesting that reduced miR-34a expression might play an important role in the malignant potential of HGSC through upregulation of the IL-6R/STAT3 signaling pathway. Moreover, we demonstrated that replacement of miR-34a reduced tumorigenicity of HGSC in vivo. Therefore, this study may provide the rationale for miR-34a replacement as a promising therapeutic strategy for HGSC. Impact Journals LLC 2019-08-06 /pmc/articles/PMC6690672/ /pubmed/31448054 http://dx.doi.org/10.18632/oncotarget.27117 Text en Copyright: © 2019 Yokomizo et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Yokomizo, Ryo Yanaihara, Nozomu Yamaguchi, Noriko Saito, Misato Kawabata, Ayako Takahashi, Kazuaki Takenaka, Masataka Yamada, Kyosuke Shapiro, Jason Solomon Okamoto, Aikou MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma |
title |
MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
|
title_full |
MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
|
title_fullStr |
MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
|
title_full_unstemmed |
MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
|
title_short |
MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
|
title_sort | microrna-34a/il-6r pathway as a potential therapeutic target for ovarian high-grade serous carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690672/ https://www.ncbi.nlm.nih.gov/pubmed/31448054 http://dx.doi.org/10.18632/oncotarget.27117 |
work_keys_str_mv | AT yokomizoryo microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT yanaiharanozomu microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT yamaguchinoriko microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT saitomisato microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT kawabataayako microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT takahashikazuaki microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT takenakamasataka microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT yamadakyosuke microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT shapirojasonsolomon microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma AT okamotoaikou microrna34ail6rpathwayasapotentialtherapeutictargetforovarianhighgradeserouscarcinoma |